Literature DB >> 12734097

Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.

Faheez Mohamed1, Pierre Marchettini, O Anthony Stuart, M Urano, Paul H Sugarbaker.   

Abstract

BACKGROUND: Hyperthermia enhances the cytotoxicity of some chemotherapeutic agents. We have studied the effect of moderate hyperthermia (41.5 degrees C) on the cytotoxicity of five new chemotherapeutic agents (docetaxel, paclitaxel, irinotecan, oxaliplatin, and gemcitabine) and melphalan against a spontaneous murine fibrosarcoma.
METHODS: The tumor was an early-generation isotransplant of a spontaneous C3Hf/Sed mouse fibrosarcoma, FSa-II. Hyperthermia was administered by immersing the tumor-bearing foot into a constant temperature water bath set at 41.5 degrees C for 30 minutes when the tumor reached 34 mm(3). Chemotherapy was administered intraperitoneally immediately before hyperthermia. Tumor response was studied by the mean tumor growth time and the mean tumor growth delay time.
RESULTS: Hyperthermia significantly increased the tumor growth times of the animals treated with docetaxel, irinotecan, and gemcitabine at low dose and these drugs plus oxaliplatin at high dose. Docetaxel at high dose showed the greatest control of tumor growth by hyperthermia, with a 26% reduction. Concerning the taxanes, paclitaxel cytotoxicity was not enhanced by hyperthermia, but docetaxel was enhanced by hyperthermia at both doses of drug.
CONCLUSIONS: Moderate hyperthermia increases the cytotoxicity of docetaxel, irinotecan, and gemcitabine on mouse fibrosarcoma. Paclitaxel did not show heat enhancement. Oxaliplatin and docetaxel showed greater heat enhancement when the drug dose was high.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734097     DOI: 10.1245/aso.2003.08.006

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  37 in total

1.  A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy.

Authors:  Tristan D Yan; Christopher Qian Cao; Stine Munkholm-Larsen
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

2.  Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model.

Authors:  Wim Bouquet; Steven Deleye; Steven Staelens; Lieselotte De Smet; Nancy Van Damme; Isabelle Debergh; Wim P Ceelen; Filip De Vos; Jean Paul Remon; Chris Vervaet
Journal:  Pharm Res       Date:  2011-03-18       Impact factor: 4.200

Review 3.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

4.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

5.  HIPEC Methodology and Regimens: The Need for an Expert Consensus.

Authors:  Aditi Bhatt; Ignace de Hingh; Kurt Van Der Speeten; Martin Hubner; Marcello Deraco; Naoual Bakrin; Laurent Villeneuve; Shigeki Kusamura; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2021-06-17       Impact factor: 5.344

6.  Inhibitory effects of mild hyperthermia plus docetaxel therapy on ER(+/-) breast cancer cells and action mechanisms.

Authors:  Feng Lv; Yang Yu; Bin Zhang; Dong Liang; Zhao-Ming Li; Wei You
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-12-13

7.  Alternating Magnetic Field Controlled, Multifunctional Nano-Reservoirs: Intracellular Uptake and Improved Biocompatibility.

Authors:  Santaneel Ghosh; Somesree Ghoshmitra; Tong Cai; David R Diercks; Nathaniel C Mills; Dianna L Hynds
Journal:  Nanoscale Res Lett       Date:  2009-10-25       Impact factor: 4.703

8.  Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy.

Authors:  Olivier Glehen; Faheez Mohamed; Paul H Sugarbaker
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

9.  Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer.

Authors:  Ashish Ranjan; Compton J Benjamin; Ayele H Negussie; Saurin Chokshi; Paul H Chung; Dmitry Volkin; Nitin Yeram; W Marston Linehan; Matthew R Dreher; Peter A Pinto; Bradford J Wood
Journal:  Pharm Res       Date:  2016-06-24       Impact factor: 4.200

Review 10.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.